Shield Therapeutics submits IND application for Phase III trial of iron-replacement therapy

Shield Therapeutics has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) to begin a Phase III trial of its novel oral ferric iron-replacement therapy ST10 for the treatment of iron deficiency anaemi…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news